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91. INTRODUCTION
Approximately 1% of all tumours arise in individuals with hereditary neoplastic
syndromes. More than 20 of these hereditary syndromes have been defined, and eight of
them predispose to tumours in the nervous system61. Most of the syndromes demonstrate
a dominant pattern of inheritance and loss-of-function mutations in specific tumour
suppressor genes. According to Knudson’s “two-hit” hypothesis, the inherited first “hit”
of a suppressor gene is recessive and the inactivation of the normal allele by somatic
mutations initiates tumorigenesis. Typically, the affected individuals develop at young age
multiple tumours of amazingly few histologic types at restricted target tissues.
Neurofibromatosis 2 (NF2) is a tumour suppressor syndrome that predisposes to benign
but multiple tumours of the nervous system, i.e. schwannomas, characteristically at both
vestibular nerves, meningiomas, and spinal ependymomas. Consistent with the two-hit
model, a germ-line NF2 gene mutation is present in every cell of the body, and
inactivating mutations are found in both alleles of the NF2 gene in the NF2-associated
tumours. Two-hit inactivation of the NF2 gene is found also in their much more common
sporadic counterparts. Thus, multiple early-onset tumours in NF2 are explained by the
need of only one additional mutation instead of two at the somatic level. The clinical
course of NF2 ranges from mild and late-onset disease to devastating forms leading to
early death from multitumour disease. There are also individuals with schwannomatosis,
a condition with multiple schwannomas, but no other manifestations of NF2. The
association of this disorder with NF2 is not clear.
The NF2 gene protein product is a novel protein with yet unidentified functions. It was
named merlin (for moesin-ezrin-radixin-like protein) because of structural similarity with
the ERM family of proteins, ezrin, radixin and moesin. ERM proteins function as linkers
between the cytoskeleton and plasma membrane, and may be involved in cellular adhesion
and in signal transduction. It is crucial to reveal merlin’s functional mechanism for the
development of a specific antitumour therapy for this single-gene disease.
The relevance of studying rare NF2 arises from the fact that defects in NF2 tumour
suppressor gene are the initial steps also in the pathogenesis of the much more common
sporadic tumours of the nervous system. This thesis on NF2 aims to analyze the
genotype-phenotype correlation in a large pedigree with extremely mild and uniform
disease, and the molecular background of schwannomatosis. Furthermore, in order to
understand the tumour suppressor mechanism of merlin, the normal function of merlin
was studied, and compared to ezrin, the prototype member of the ERM family.
10
2. REVIEW OF THE LITERATURE
2.1. Neurofibromatosis 2
2.1.1. Neurofibromatosis 1 (NF1) and 2 (NF2) - two different diseases
Neurofibromatosis 1 (NF1), previously known as peripheral or von Recklinghausen's
neurofibromatosis, and neurofibromatosis 2 (NF2), previously known as central
neurofibromatosis or bilateral acoustic neurofibromatosis, are both inherited tumour
suppressor syndromes. NF2 predisposes to multiple schwannomas, meningiomas and
spinal ependymomas of the central nervous system, with bilateral vestibular nerve
schwannomas as the classic diagnostic hallmark, and few non-tumour manifestations70.
The more common NF1 (insidence 1:4000) predisposes to multiple skin neurofibromas,
iris hamartomas (Lisch nodules), optic pathway gliomas and astrocytomas,
pheochromocytomas, leukemia and malignant peripheral nerve sheath tumours, but not to
NF2-associated tumours207.
The first description of NF2 was probably by Wishart in 18223. The patient had multiple
intracranial tumours arising from the dura and cranial nerves and also from both internal
auditory meati, with no cutaneous features. When the German neuropathologist Friedrich
von Recklinghausen reported cases of NF1 with neurofibromas in 1882213, NF1 and
NF2 cases became collectively referred to as von Recklinhausen’s disease182. The final
separation in to two distinct diseases came in 1987, when the NF1 gene was mapped to
chromosome 1716 and the NF2 gene to chromosome 22154. This led to the establishment
of the following diagnostic criteria by the National Institute of Health (NIH) Consensus
Group clearly separating NF1 and NF21.
A clinical diagnosis of NF1 can be made if two or more of the following conditions are
met: 
1. Six or more café-au-lait macules, over 15 mm in diameter.
2. Two or more neurofibromas or one plexiform neurofibroma.
3. Axillary or inguinal freckling.
4. Optic glioma.
5. Two or more iris hamartomas, "Lisch nodules".
6. Typical bony changes like sphenoid dysplasia or thinning of the cortex of long bones.
7. A first degree relative with NF1.
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The NIH diagnostic criteria for NF2:
1. Bilateral eight nerve masses; or
2. A first-degree relative with NF2 and either a unilateral eight nerve mass,
or two of the following: neurofibroma, meningioma, glioma, schwannoma, or juvenile
posterior subcapsular lenticular opacity.
2.1.2. NF2 Genetics
The inheritance of NF2 is autosomally dominant. About half of the NF2 cases represent
new mutations, which gives a high calculated mutation frequency for the NF2 gene, 7.5
x10-6, partly reflecting the low reproductive fitness of severe sporadic cases56. The
penetrance of clinical NF2 is age-dependent and considered complete by age 60
years55,57.
When the gene for NF2 was mapped to chromosome 22, in 1987,154 predictive testing by
linkage analysis became possible in families (  > 2 affected)138,159. All familial NF2 cases
have been linked to this region, suggesting that NF2 is a single-gene disease59,138. The
cloning of the NF2 gene155,197, in 1993, made direct mutation detection possible.
However, the detection of mutations is very laborious due to a large variation in the type
and location of NF2 gene mutations, almost always different in unrelated individuals121.
Somatic mosaicism, apparently rather common in NF260,100, leads to a lower
transmission risk and can cause misleading linkage results24.
2.1.3. Epidemiology
Only two epidemiological studies on NF2 have been published. Evans and associates
found 19 NF2 cases in a population of 4 016 100, a diagnostic prevalence of 1 in 210
000, and estimated the birth incidence of 1 in 33 000-40 56256. Antinheimo and
associates reported a clearly lower incidence, 1 in 87 410, in southern Finland11,
probably because the study was based on medical records, while in England also the
relatives at risk were screened by CT or MR imaging.
2.1.4. Clinical manifestations
Bilateral schwannomas of the vestibular (8th cranial) nerve, the hallmark of NF2, develop
in virtually all cases54, and multiple schwannomas of other cranial nerves occur in more
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than one third54,131,141. Schwannomas affect primarily the sensory nerves and spinal
dorsal roots54,113. Meningiomas, often multiple, are seen intracranially in half of the
patients54,131,141. Characteristic of NF2 are also the multiple spinal tumours seen in MRI
scans in up to 90% of patients51,54,130,131. The spinal tumours are typically
schwannomas, meningiomas, or mainly asymptomatic intramedullary
ependymomas54,73,110,130,131,141.
Skin tumours arising from peripheral nerves seen in over half of NF2 patients are
predominantly schwannomas, but also some neurofibromas occur54,73,132,141. One third
of NF2 patients have skin café-au-lait macules, but only in less than 2% their number
reaches six, one of the diagnostic criteria for NF154,132,141.
Another diagnostic hallmark of NF2 are ocular abnormalities, cortical and posterior
subcapsular or capsular cataract, retinal hamartomas and epiretinal membranes,
encountered in over 90% of cases92,131,142,150.
NF2 patients display also other lesions of the nervous system including asymptomatic
schwannosis (proliferation of Schwann cells), glial hamartias, meningioangiomatosis and
intracranial calcification, and polyneuropathy115,157,212.
Several large clinical studies have confirmed the clinical picture of NF254,93,131,141.
Based on the clinical picture, additional diagnostic criteria were proposed55, because the
original NIH criteria seemed to be too rigid1.
Current   diagnostic    criteria  for     N F 2 55 :   
Bilateral vestibular schwannomas (VS) OR family history of NF2 plus
1. Unilateral VS or
2. Any two of: meningioma, glioma, neurofibroma, schwannoma, posterior subcapsular
lenticular opacities (SLO).
or (additional criteria)
1. Unilateral VS + Any two of: meningioma, glioma, neurofibroma, schwannoma, SLO
or
2. Multiple meningiomas (2 or more) + unilateral VS or any two of: glioma,
neurofibroma, schwannoma, cataract, cerebral calcification.
The best diagnostic examination is the magnetic resonance imaging (MRI) with
gadolinium contrast enhancement of the entire neuraxis, complemented with eye and skin
examination. To exclude NF2, repeated investigations should be considered if the
individual has a family history of NF2, unilateral vestibular schwannoma or meningioma
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at age < 30 years, multiple spinal tumours, or café-au-lait macules and skin tumours
insufficient for a diagnosis of NF1.
2.1.5. Clinical course
The severity of NF2 ranges from mild (late onset at   > 30 years; slowly growing vestibular
schwannomas; few other manifestations) to aggressive (early onset at  < 20 years; multiple
rapidly growing tumours causing early death in the 3rd or 4th decade)56. The onset of
symptoms and manifestations has varied between age 2 years and the 5th
decade54,57,131,141. The mean age at onset of symptoms is about 20 years, the diagnosis
is made 8 years later, and mean life span is about 40 years54,141. In most cases, the initial
symptoms are due to vestibular schwannomas, hearing loss, tinnitus, balance problems or
vertigo54,131,141. Young patients are likely to present symptoms from skin and spinal
tumours or ocular manifestations54,129,141.
NF2 generally demonstrates intrafamilial similarity in its course52,54,141, but some
families present with both mild and severe phenotypes17,98,141,171, and monozygotic
twins are not identical18.
2.1.6. Treatment of NF2 tumours
In NF2, the majority of tumours grow slowly, and gradually cause symptoms by
compressing the adjacent structures. Complete microsurgical removal is the treatment of
choice, but the tumours are also amenable to stereotactic radiotherapy. The management
of bilateral vestibular schwannomas is especially demanding because of the high
probability of hearing loss in both ears, facial nerve paresis and disequilibrium. The
treatment of tumours must take into account tumours elsewhere in the nervous system or
the need of repeated interventions due to later arousal of other tumours. Thus, the timing
of the intervention and the treatment option should be evaluated individually for each NF2
patient.
Available treatment for bilateral vestibular schwannomas includes: 1) observation without
surgical intervention; 2) bony decompression of the internal auditory canal; 3) partial
tumour removal; 4) complete removal with auditory brainstem implant; 5) total tumour
removal with attempted hearing preservation; and 6) stereotactic radiation35. However, in
NF2-associated tumours hearing preservation and the recovery of facial nerve has been
less successful than in non-NF2 vestibular schwannomas26,27,166. A less favourable
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outcome is also seen in NF2-associated spinal schwannomas compared with sporadic
tumours96. Recently at centres of expertise, there are promising reports of a fair chance
(up to 65%) of hearing preservation with excellent facial nerve recovery in small
completely resected NF2-associated vestibular schwannomas166,185 and similar success
rates for stereotactic radiation (tumours with diameter < 30 mm)190. However, in severe
NF2, multiple meningiomas with aggressive growth may be uncurable by surgery or
radiotherapy. Other treatment options are limited, although some results have been
obtained with hydroxyurea, antiestrogen and antiangiogenic compounds126,170,193. The
usefulness of targeted treatments, such as vector-mediated NF2 gene transfer with
response in primary meningioma cultures86, remains to be seen.
2.2. Schwannoma and meningioma
2.2.1. Schwannoma
A schwannoma (previously neuroma or neurilemmoma) is almost always a benign (grade
I, WHO), slowly growing and sharply demarcated tumour of the cranial, spinal, and
peripheral nerves, with sensory nerves as the preferred site216. Schwannomas account for
an estimated 8% of all intracranial and one fourth of spinal tumours in adults, and the
approximated annual incidence of vestibular schwannomas is 1.2 tumours/100 000196
and spinal schwannomas 0.3-0.4/100,000177. The incidence of peripheral nerve
schwannomas is not known. For an unknown reason, most intracranial schwannomas
originate from the vestibular part of the eighth cranial nerve in the cerebello-pontine
angle14. The peak incidence of sporadic schwannomas is in the fourth to sixth decades of
life, and they occur approximately equally in both sexes at all ages216.
Morphologically, schwannomas are usually encapsulated tumours composed of spindle-
shaped Schwann cells with elongated nuclei. The growth pattern consists of Antoni A
areas, represented by closely packed tumour cells, and Antoni B areas, where the tumour
cells are loosely arranged. Sometimes the cells are arranged in a palisade fashion with
their nuclei aligned, occasionally forming roundish Verocay bodies. Schwannomas differ
from neurofibromas, the hallmark tumours in NF1, which are non-encapsulated tumours
composed mainly of the cell types forming the fine ordered supportive compartments of
peripheral nerves, but organized in a haphazard way.
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Bilateral vestibular schwannomas, the indicators of NF2, represent 8.5% of all vestibular
schwannomas165. In general, NF2-associated schwannomas are similar to their sporadic
counterparts, but there are also differences. NF2 tumours present at an earlier age, are
multiple, and show a lobular "grape-like" growth pattern at both macroscopic and
microscopic examination, extremely uncommon in sporadic schwannomas186. NF2
schwannomas demonstrate higher proliferation potential (MIB-1)2,8 and more foci of high
cellularity186, suggesting more aggressive behaviour. NF2-associated vestibular
schwannomas more often contain embedded nerve fibres of the adjacent facial nerve than
sporadic schwannomas74,91,123. Consequently, preservation of the continuity and
function of the facial and cochlear nerves during surgery is more difficult in NF2166.
Cytogenenetic and molecular studies show that deletions on 22q occur in the majority of
sporadic schwannomas, and chromosome 22q seems to be the only constant
chromosomal region involved in the pathogenesis of schwannomas10,42,173.
2.2.2. Schwannomatosis
Multiple schwannomas (  > 2) without other manifestations of NF2, a condition termed as
schwannomatosis (neurilemmomatosis) may be a separate entity from NF2120,148,181. In
the earlier reports of schwannomatosis, many cases actually fulfill the diagnostic criteria
of NF21,120. Convincing evidence of a distinct disease entity came from the patient series
of MacCollin et al.120, who carefully excluded NF2, confirmed the tumour histology, and
demonstrated the lack of family history suggesting a non-inherited condition. Some
patients had a highly localized disease, suggesting a possible segmental mutation of the
NF2 gene, whereas other individuals had a more general disease possibly due to a tumour
suppressor gene syndrome120. The candidates for the genetic syndrome could be (1)
NF2, at the mildest end of the clinical spectrum, which is supported by the identification
of a germ-line NF2 mutation in a schwannomatosis patient82; (2) another locus,
predisposing to the development of schwannomas; or (3) NF1, although unlikely, since
tumours in NF1 are almost exclusively neurofibromas not schwannomas53.
2.2.3. Meningioma
Meningiomas are usually slowly growing tumours attached to the dura, composed of
neoplastic meningothelial (arachnoidal) cells. Meningiomas are graded according to signs
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of anaplasia into three categories (WHO): Grade I (90%), Grade II (atypical) or Grade III
(anaplastic)114. The histological subtypes in Grade I meningiomas are meningothelial
(53%), transitional (28%), and fibrous (8%)105. Meningiomas constitute 20% of all
primary intracranial tumours, they occur in 2.3/100 000 population and show a male-to-
female ratio of 1:228. Meningiomas are rare in childhood and adolescence, and their
incidence increases with age with a peak in the 7th decade28. Most meningiomas are
asymptomatic and go unnoticed if not found incidentally on neuroradiological examination
or autopsy (found in 1.4% of autopsies)151.
In some sporadic cases (4-10%), meningiomas are multiple11,114. Interestingly, multiple
tumours from patients with more than two lesions have shown to be clonal in origin,
suggesting a subarachnoidal spread from a single progenitor cell109,187,206,220. In
extremely rare cases meningiomas may be familial without any signs of NF2133,183, and
at least in one such family the NF2 gene locus was excluded, suggesting a different
meningioma predisposition gene146. No cases of familial meningiomatosis were found in
a population of 1.6 million in Finland11.
In general, multiple meningiomas or their occurrence at young age suggests NF2. Most
NF2 meningiomas are also of WHO grade I, but more frequently of fibroblastic type115,
and demonstrate more aggressive growth (higher MIB-1 indices) than sporadic
meningiomas9.
Cytogenenetic and molecular studies show that deletions on 22q occur in the majority of
sporadic meningiomas of all malignancy grades, suggesting that inactivation of this
chromosomal region represents an early genetic event in the pathogenesis of
meningiomas161. In atypical and malignant meningiomas, other regions than 22q seems
to be associated with malignant progression, as suggested by frequent losses on
chromosomes 1p, 6q, 9q, 10q, 14q, 17p and 18q, and chromosomal gains, most
commonly on 20q, 12q, 15q, 1q, 9q and 17q95,108,209.
2.3. NF2 gene
Frequent loss of alleles on chromosome 22 in NF2-associated schwannomas and
meningiomas, and genetic linkage analyses of large NF2 families located the defect, in
1987, to 22q11.1-22q13.1154,173-175,211. In 1993, the NF2 gene, with germ-line
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mutations in NF2 patients, was cloned by two separate groups155,197. Mutations in both
alleles of the NF2 gene in tumor tissue confirmed the two-hit pathogenetic mechanism of
tumour suppressor genes, earlier proposed by Knudson for retinoblastoma101.
2.3.1 Structure
The NF2 gene at 22q12.2 contains 17 exons and an open reading frame of 1785
nucleotides encoding a 595 amino acid protein155,197. The first intron contains a highly
polymorphic CA-repeat marker, NF2CA3, and four biallelic DNA variants immediately
flank the NF2 gene31,221. The NF2 gene is phylogenetically conserved and is found in C.
elegans and Drosophila202. The cloned mouse gene shows 90% cDNA sequence identity
with the human NF2 gene41,72.
2.3.2. Tissue expression and alternative splicing
The NF2 gene is expressed widely despite the restricted phenotype of the NF2 disease.
Two major NF2 RNA transcripts of 2.6 and 7 kb, and a weaker one at 4.4 kb, are
detected in adult human kidney, lung, breast, ovary, brain, liver, and pancreas21. In rat
and mouse the wide foetal expression is restricted to the adult distribution pattern during
the embryonic development68,84. In adult rats and mice, NF2 expression is detected by
RT-PCR in the central nervous system (cerebral cortex, brainstem, cerebellum, spinal
cord), dorsal root ganglia, testis, ovary, adrenal gland tissues and cultured Schwann
cells. By in situ hybridization, the expression in the nervous system is restricted to
neurons of the hippocampus, brainstem (pons, mid-brain, medulla), facial and trigeminal
motoneurons, neurons in vestibular and coclear nuclei, cerebellum (Purkinje and granule
cells, locus coeruleus, reticular nuclei), spinal cord (neurons in the gray matter) and
primary sensory neurons in the dorsal root ganglia68.
Two major mRNA isoforms, I and II, result from alternative splicing of the last two
exons (16/17)21. They are expressed at about equal levels, and have a tissue-specific and
a development-specific expression level in human, mouse and rat cells68. In the human
nervous system, cultured Schwann cells and pure glial cultures express relatively more
isoform I than II68. Several other alternatively spliced NF2 transcription products have
been identified in normal human tissues involving exons 1a (within intron 1), 2, 3,
1513,149, and also exon 881 and exon 10149. The isoform III (also termed E2 or D208),
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splice variant without exon 15 and 16, is detected at low levels in various human
tissues13,149 but not at all in mouse or rat68. Recently three new splice variants have been
shown to be expressed in fibroblasts, lymphoblasts and adult retina but not in other adult
tissues: Mer151 with exons 1/4/8/9/10/13/14/17 and Mer150 with exons 9-13 and
Mer162 with exons 5-16 skipped169. The biological significance of the isoforms and the
mechanisms that regulate their expression is not known.
Figure 1. The COOH-terminal NF2 gene isoforms I, II, and III, respectively, result from alternative
splicing of exons 15, 16 and 17. The number of residues contained in each polypeptide is indicated. An
asterisk denotes the merlin COOH-terminus.
2.3.3. Germ-line Mutations
Over 200 germ-line NF2 gene mutations have been reported, including all different types
of mutations12,23,30,32,43,59,82,87-89,98-100,117-119,135,142,155,162-164,167,171,197,203,208,
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. The mutations span the entire gene, except the variantly spliced last exon 16/17,
without mutational hot spots121. Nonsense mutations due to C to T transitions in five of
the six CGA codons in exons 2, 6, 8, 11 and 13, are especially frequent164. The
nonsense, frameshifting and splice site mutations predicted to cause premature translation
termination and protein truncation account for a vast majority of all NF2 mutations121
(Table 1).
Table   1.     Ger    m-line     NF2     mutations  a                                                            
Exons: 1 2 3 4 5 6 7 8 9
Mutations  (no): 13 26 15 6 10 19 11 22 1
Exon size (bp) b : 114 126 123 84 69 83 76 135 75
                                                                                                                                                  
Exons: 1 0 1 1 1 2 1 3 1 4 1 5 1 6 1 7
Mutations  (no) 11 26 18 10 10 17 0 0
Exon   size  (bp): 114 123 218 106 128 163 45 47
                                                                                                                                                   
aReported NF2 mutations; a mutation map is accessible at http://neuro-trials1.mgh.harvard.edu/nf2/
bExon size and numbering according to Jacoby et al.87
exon17/47bpexon16/45bpexon15/163bpexon14/128bp
Isoform I
Isoform II
Isoform III
L TLQSAKSRVAFFEEL
PQAQGRRPICI
N SPCRAPSPEWPSLKSSSR
595 aa
590 aa
543 aa
K .........SDRGGSSKHNTIKK.....EKE
.....EKE
.....EKE
K ..........SDRGGSSKHNTIKK
*
*
*
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In NF2, the mutation detection rate by exon screening (SSCP and DGGE) has been low
(34 to 66%)59,98,118,135,142,162. This is seen especially in mild cases, possibly due to the
inability to detect large deletions or low level somatic mosaicism, both associated with
mild disease59,60,142,221. Recently, mutation search by combining different molecular
methods has revealed a significant proportion of large deletions (6 out of 16 mutations)
increasing the mutation detection rate to about 85%221.
2.3.4. Genotype-phenotype correlation
There is some correlation between the type of mutation and the severity of NF2 (age of
onset, hearing loss and diagnosis, and number of tumours)59,98,121,135,142,162. No effect
of the position of the mutation has been noted in NF2. Truncating mutations typically
associate with a severe disease, whereas missense and splice site mutations, and also
large deletions associate with milder NF259,135,142,162. In severe cases, truncating
mutations are seen in 86%, splice mutations in 49%, and missense in only 33%121.
Splice donor site mutations associate with milder disease than splice acceptor mutations,
although exceptions occur59,98,99,135,142,162. The unpredicted outcome, also within
families, is associated especially with splice site mutations99. Also, truncating mutations
usually associated with severe NF2, may cause mild disease in a somatic mosaic29,89,100.
Furthermore, phenotypic variability (tumour burden) seen in monozygotic twins suggests
that the outcome depends also on stochastic events, such as loss of the second NF2
allele18. Altogether, in individual cases, cautiousness is suggested in the prediction of
outcome based on the mutation type59.
2.3.5. Somatic mutations
In two-thirds of NF2-associated tumours and their sporadic counterparts, two different
NF2 gene mutations have been found in the same tumour. Often seen as a single mutation
combined with a loss of the normal allele, detected as loss of heterozygosity of
polymorphic markers at NF2 region or entire chromosome 2250,88,160. Inactivation of at
least one allele of the NF2 gene is seen in most sporadic counterpart tumors, i.e. in over
90% of sporadic schwannomas88. This provides strong evidence for a NF2 gene tumour
suppressor mechanism in NF2-associated and sporadic schwannomas, meningiomas and
ependymomas.
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In tumours, the vast majority of somatic NF2 gene mutations are predicted to cause a
truncation of the protein product, similar to germ-line mutations. However, somatic
mutations are more often out-of-frame deletions or insertions than base substitutions121.
The mutations in schwannomas span throughout the NF2 gene88, while mutations in
meningiomas may be more unevenly distributed, affecting mainly exons 1 to 13 (majority
in exons 1-8)44. In sporadic meningiomas, NF2 gene mutations are found mainly in the
tumours of the fibroblastic and transitional type (70 to 80%) and less in the meningothelial
type (25%)115,210. In some meningiomas, other genes on chromosome 22q have been
shown to be disrupted, for example the ß-adaptin (BAM22)144 and the MN1 gene112.
Sporadic benign meningiomas without allelic losses on 22q have displayed deletions in 1p
and 3p, suggesting that these regions may contribute to meningioma tumorigenesis in a
subset of cases38. Most of the WHO grade II sporadic spinal ependymomas harbour NF2
gene mutations25,50.
Cytogenetic aberrations and DNA sequence copy number losses in 22q involving the NF2
gene region have been detected in some tumour types not associated with NF2102. NF2
gene mutations have been demonstrated frequently in malignant mesotheliomas (MM),
especially in MM cell lines22,39,45,176, and occasionally in melanomas, colon and breast
carcinomas13,21. The presence of NF2 mutations in non-NF2 tumours with an array of
other genetic aberrations suggests a role for the NF2 gene in the progression of other
malignancies111.
2.4. NF2 gene product, merlin
2.4.1. Homology with ERM proteins
The NF2 gene product, merlin197 or schwannomin155 or NF2 protein, is a 595-amino acid
protein with a predicted molecular weight of
 
66 kDa. Merlin demonstrates sequence similarity
with the ERM proteins, ezrin, radixin and moesin, three highly homologous membrane-
cytoskeleton linker molecules15,122,199,204. ERM proteins belong to a larger superfamily of
band 4.1 proteins, which includes as its prototype the erythrocyte band 4.1 protein with its
many homologues, several protein tyrosine phosphatases and talin122. Merlin shares the
predicted overall domain structure of ERM proteins, which consists of a globular N-terminal
domain (~1-310 amino acids in merlin), an α-helical region (~300-470 aa), a proline rich
strech between the α- and C-domain, and a charged C-terminal domain (~470-595). Merlin
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demonstrates highest homology to the ERM proteins in its N-terminal domain with over 60%
identity, while the homology in α-helical and C-terminal domains is only 20-30%202 (Figure
2). The homologous ~300-amino-acid FERM (F for 4.1 protein, E ezrin, M moesin, R
radixin) domain is present in all band 4.1 superfamily members and in some other
molecules such as myosin VIIA40.
Figure 2. Overall domain organization of ERM proteins, human and Drosophila merlin. The globular N-
domain is the most homologous region termed as FERM, followed by an α-helix. α  - and C-domains are
likely to have an extended conformation and are separarated by a polyproline-strech. The C-terminal actin-
binding site ( n )  is shown. Length is in amino acids.
2.4.2. Distribution of merlin and ERM proteins
Ezrin, radixin and moesin are concentrated in actin-enriched specialized plasma membrane
structures, such as microvilli, filopodia and membrane ruffles33. Cultured cells usually
express all ERM proteins, and all cell types within the body express one or more of the
ERM proteins, but their expression pattern in tissues is cell-type specific20. Although the
subcellular distribution of all ERM proteins seems to be very similar, this is not always the
case. In cytokine-stimulated motile T lymphocytes, ezrin is distributed homogeneously in
the cytoplasm, whereas moesin is located preferentially at the tip, and radixin in the neck of
uropods178.
Ezr in585
LengthFERM domain
576 Moesin
86% 61% 62%
Dro s op hi la
merlin
634
55% 21% 24%
Merlin595
61% 30% 22%
Radixin582
N-domain C-domainα-helix
86% 69% 61%
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Although NF2 RNA expression indicated wide distribution, merlin is detected mainly in
human epithelia, mesothelium, smooth muscle, endothelial cells, neurons of the central
nervous system, Schwann cells, arachnoidal cells and faintly in glial and ependymal
cells47,48,85,163,168,188,189. Some discrepancy between immunohistochemistry and
mRNA-in-situ-hybridization results may be due to the low expression of merlin in some
tissues.
2.4.3. Function of ERM proteins
ERM proteins are membrane-cytoskeleton linkers involved in the organization of the
cortical cytoskeleton, formation and maintenance of membrane structures, cell migration
and adhesion. The overlapping functions of ERM members are highlighted by the finding
that all membrane projections disappear and cellular adhesions are disrupted when
expression of all three ERM proteins is blocked by antisense oligonucleotides194. The
linker mechanism of ERM proteins is based on their ability to bind the cytoplasmic
domains of transmembrane proteins through the N-terminal FERM domain and to anchor
actin microfilaments. ERM proteins interact directly with the cytoplasmic domain of cell
surface adhesion molecules such as CD44 (hyaluronate receptor), CD43 (sialophorin),
and intercellular adhesion molecules, ICAM-1, -2 and -376,77,198,218,219. ERM proteins
bind also indirectly to plasma membrane through interaction with EBP50 (for ezrin-
binding-protein) and E3KARP molecules which have PDZ domains, known to bind to
cytoplasmic tails of specific membrane proteins153. F-actin interaction sites have been
mapped to the last 34 C-terminal amino acids and to the N-terminal domain of ERM
family members143,156,201.
A characteristic feature of ERM proteins is their ability to self-associate, oligomerize and
bind to each other by head-to-tail joining20,63. The two interacting domains, defined as
N- and C-ERMADs (for ERM association domains) regulate the functional activity of
ERM proteins by masking binding sites for other molecules such as actin or
transmembrane proteins. Thus, soluble full length molecules are in a “closed” or
“dormant” state in which the biologically relevant binding sites are masked. Activation of
the ERM proteins is proposed to occur through a conformational change, possibly by
phosphorylation and by interaction with phosphoinositide phosphatidylinositol 4,5-
bisphosphate (PIP2), which relieves the interaction between N- and C-domains128,137.
The open form of the molecule allows phosphorylation of the conserved Thr residue
within the F-actin binding region by Rho-kinase and protein kinase C-θ34,127,128,137,145.
Activation unmasks the F-actin and EBP50 binding sites, increases binding, and causes a
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translocation of the ERM proteins from the soluble pool to the membrane-skeleton while
dephosphorylation reverses the effect122,184. Also the secondary messenger
phospholipid, PIP2, known to conformationally regulate several cytoskeletal components,
binds the N-terminal part of ezrin and enhances the interaction between ezrin and
transmembrane proteins79.
An apparently important function of ERM proteins is their yet incompletely understood
role in the Rho and cAMP-dependent protein kinase A (PKA) signalling pathways. ERM
proteins serve as anchoring sites for proteins of intracellular signalling cascades such as
Rho-GDP dissociation inhibitor (GDI), Rho-GDP/GTP exchange factor Dbl191,192 and a
regulatory subunit of PKA49. Also, ezrin associates with the E-cadherin/β-catenin
complex, which has a role in the control of cell proliferation19,80. ERM proteins may
serve as major coordinators of cell signalling at very relevant subcellular localizations, i.e.
sites of intercellular connections, membrane protrusions of migrating cells. Although
ERM proteins are not known to associate with tumour suppression, in a recent study,
inhibition of ezrin expression by antisense oligonucleotides caused increased invasion in
colorectal cancer cells80. Other reports have suggested that ezrin may be linked to
increased proliferation and cell survival. Abnormal or high expression of ezrin is
associated with transformation and increased proliferation94 and ezrin is an integral
component in the cell survival machinery by conveying antiapoptotic signals64,106.
2.4.4. Tumour suppressor function of merlin
Several lines of evidence indicate a direct growth suppressor function for merlin. Most
schwannomas, meningiomas and malignant mesothelioma cell lines demonstrate
inactivation of the NF2 gene and absence of merlin39,45,71,113. Knock-out heterozygous
(NF2+/-) mice develop a variety of highly metastatic tumours which have lost both NF2
alleles134, and in Drosophila, loss of the respective NF2 homologue (Dmerlin) results in
cellular overproliferation107. In vitro, merlin suppresses the growth rate of NIH-3T3
cells116 and reverses the malignant phenotype, i.e. anchorage-independent growth, of
Ha-ras-transformed cells195. Also, an increase in the expression of merlin due to
increased confluency suggests a role in the contact inhibition of cell growth179. This is in
line with the cell detachment and increased proliferation seen in response to antisense
oligonucleotide inhibition of merlin expression83. In experimental models, the potential to
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inhibit cell growth is associated with isoform I, whereas neither isoform II, nor constructs
truncated at amino acid 547 of the C-terminal domain, possess such a function116,180.
3. AIMS OF THE STUDY
The specific aims of this study were:
1. to characterize the clinical course of NF2 in a large Finnish pedigree.
2. to identify the mutation causing very mild NF2 and to study its consequences at the
RNA and protein level.
3. to determine whether the NF2 gene is involved in the etiology of schwannomatosis.
4. to determine whether the NF2 gene product, merlin, is functionally a member of the
ERM protein family.
4. PATIENTS AND METHODS
4.1. Clinical investigation (Studies I and III)
Patient ascertainment: A large Finnish NF2 pedigree included 65 descendants in four
generations (I). Patients with two or more schwannomas were identified from a cohort of
243 patients operated on for spinal schwannoma at the Department of Neurosurgery,
Helsinki University Hospital (III). A clinical examination was done to detect any
neurological abnormalities, skin manifestations or peripheral tumours. The patients were
questioned for family history suggestive of NF2 or NF1: any tumours, hearing loss,
ocular changes or skin pigmentation. The otological examination included audiometry,
brainstem auditory evoked responses, and posturography (I). The ophthalmological
examination included biomicroscopy of the iris and the lens, measurement of the density
of the lens, and dilated fundus examination with an indirect ophthalmoscope (I, III). MRI
(Study I/1.0 T and Study III/ 0,23 T) of the head and spine was performed with a with
gadolinium-contrast enhancement. Review of the histological specimens was
performed for the operated schwannomas (I, III) and 20 sporadic controls (III). Death
certificates for the deceased patients were obtained from Statistics Finland (I, III).
The written informed consent of the family members was obtained prior to the
examinations. Data were given to family members only if requested. The results of the
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presymptomatic molecular testing were given, if requested by a clinical geneticist
counselling a family member. The study protocol was approved by the ethical committees
of the Departments of Otology, Neurosurgery, Neurology and Radiology, Helsinki
University Central Hospital.
4.2. Linkage and LOH analysis (I, II)
DNA was extracted from peripheral blood leukocytes of 73 members, or skin fibroblasts
from three family members, and five tumours (stored at -80o C). Three of the tumours
were surgically removed vestibular schwannomas and two were obtained at autopsy.
Four polymorphic flanking markers in the vicinity of the NF2 gene were used: a HincII
polymorphism at the human heavy neurofilament subunit gene (NEFH); and three CA-
repeat polymorphisms, CRYB2 at the beta-crystalline 2 gene, D22S268 and D22S280
(Genome Data Base). Two-point lod scores and the risk analyses were calculated by the
MLINK program (5.10) with the following assumptions: a female to male recombination
ratio of 1.4; an age-dependent penetrance of 0.05 (0-19 years), 0.25 (20-29 years), 0.50
(30-39 years), 0.75 (40-49 years), or 0.90 (50 years or over)211; a disease gene
frequency of 2.9 x 10-5 and a mutation rate of  6.5 x 10-6 for the NF2 gene56. The
probability of a double-recombination to occur with two nested pairs of flanking markers
was estimated at < 1%. Therefore, if the flanking markers of the NF2 gene are
informative in an individual, the risk of being affected can be given with either < 1% or >
99%, depending on which haplotype is inherited.
In the LOH analysis (II), DNA from tumour and patient fibroblasts was analyzed for the
DNA copy number with an intragenic NF2 microsatellite marker CA3 and with two
flanking markers, CRYB22 and D22S280 (Genome Data Base). LOH was considered to
be present, if the signal was less than half of the strength of the remaining allele.
4.3. Mutation analyses (I-III)
The molecular genetic DNA analysis included all 17 exons of the NF2 gene, which were
either studied by Single Stranded Conformation Polymorphism (SSCP) (II) or sequenced
using an automatic sequencer (II-III). Fibrobast RNA was converted by reverse
transcriptase and amplified (RT-PCR) with 8 overlapping pairs of oligonucleotides
covering the NF2 gene coding region and studied by gel electrophoresis and SSCP
analysis (I, II). Southern blot analysis was performed with three restriction enzymes and
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the complete [32P]CTP-labeled NF2 cDNA, kindly provided by Dr. James Gusella, was
used as a probe (I).
Identification of the NF2 gene mutation allowed us to adopt the solid-phase
minisequencing method for direct mutation detection and presymptomatic diagnosis (II).
In the minisequencing reaction with genomic DNA a detection primer hybridizing
immediately adjacent to the 1737+3 a -› t mutation was elongated with radiolabeled
nucleotides, TTP to detect the mutant t1737+3 and subsequently ATP to detect the wild-type
a1737+3.
4.4. Cell expression studies (IV)
NF2 cDNA was subcloned into the eukaryotic expression vector pcDNA3 and pREP7
(hygromycin selection marker). Monkey COS-1, Chinese hamster ovary (CHO), human
embryonic kidney-derived 293-EBNA and U251 malignant glioma cells were grown on
untreated or fibronectin coated coverslips. Transfections of COS-1 and CHO cells were
performed using the DEAE dextran and LipofectAMINE method, respectively. 293-cells
were transfected by the calcium phosphate coprecipitation method and were studied after
four weeks in hygromycin selection.
Association of merlin with the cytoskeleton was studied using two approaches, extraction
of transfected COS-1 cells with a non-ionic detergent (0.5% Triton X-100) and treatment of
cells with cytochalasin B. The comparison of the detergent-soluble and detergent-insoluble
fractions was done by the densitometric analysis option of the NIH Image program.
Detergent-extracted cells on coverslips were labeled for merlin and ezrin and with
phalloidin, and analyzed by confocal microscopy. The actin-containing cytoskeleton of
COS-1 cells was disrupted with cytochalasin B.
4.5. Antibodies (II, IV)
Four antibodies raised against NF2 cDNA-derived peptides were used: (1) 1398NF246
against residues 508-533 and (2) mAb HB746 against residues 192-209 (both kindly
provided by Drs. den Bakker and Zwarthoff), (3) anti-SCH116 against residues 566-595
(kindly provided by Dr. Rouleau), (4) anti-GST-M/S
 
rabbit antiserum against residues
131-253. Ezrin was detected with mAb 3C1237 and CD44 with mAb Hermes-390 (kindly
provided by Dr. S. Jalkanen).
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4.6. Immunoblotting (II, IV)
Cultured cells or tumour lysates, in Laemmli buffer, were separated by SDS-PAGE,
transferred to nitrocellulose sheets and used for immunoblotting. Merlin antisera, ezrin
mAb 3C12 and commercial peroxidase-conjugated secondary antibodies were used, and
the peroxidase was detected by enhanced chemiluminescense. Molecular weights were
evaluated by the NIH Image program (version 1.60).
4.7. Immunofluorescence and confocal microscopy (IV)
Transfected cells and U251 cells were stained for merlin with anti-SCH, anti-GST-M/S
and 1398NF2 antiserum followed by TRITC-conjugated secondary antibody. For double
staining of merlin and ezrin, fixed cells were incubated simultaneously with a merlin-
antiserum and mAb 3C12, followed by TRITC-conjugated goat anti-rabbit IgG and
FITC-conjugated goat anti-mouse IgG. Double staining of merlin and CD44 was carried
out as above, but the primary antibodies used were 1398NF2 and mAb Hermes-3. To
visualize merlin and F-actin, COS-1 cells grown on fibronectin-coated coverslips were
incubated with anti-SCH and TRITC-labeled phalloidin. The specimens were viewed with
a confocal 410 Invert Laser Scan Microscope. In some experiments, cell contours were
visualized with FITC-conjugated wheat germ agglutinin (WGA) and using the differential
interference contrast (DIC) option of the confocal microscope. Cell apoptosis was
analyzed by direct fluorescence detection of genomic DNA fragmentation.
Merlin and control pSVß-Galactosidase-transfected CHO cells, stained with FITC-WGA
and anti-SCH or anti-ß-galactosidase mAb, were studied by confocal microscopy using
immunofluorescence and DIC options. Transfected cells from three experiments were
measured for the largest diameter (length, d) and surface attachment area (SA) using the
morphometry software of the microscope. The significance of differences between merlin
and ß-galactosidase expressing CHO cells was calculated by the Mann-Whitney U-test.
4.8. CD44 binding assay (IV)
Recombinant merlin was produced by expressing merlin as a GST-fusion protein, using
the baculovirus expression system and Sf9 insect cells. Interaction of merlin and CD44
was studied with lysates of Namalwa human B lymphoma cells without CD44, Namalwa
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transfectants stably expressing CD444, and recombinant GST-merlin. The CD44 that was
bound to GST-merlin was detected with iodinated anti-CD44 mAb Hermes-3.
5. RESULTS
5.1. Characterization of a large pedigree with very mild and
uniform NF2 (I, II)
Linkage analysis of all family members at risk identified six manifestation-free individuals
with NF2. Clinical examination of 22 family members and gathering all follow-up data
disclosed eleven members with NF2. Nine imaged tumours, three of them asymptomatic,
have not been operated on due to slow growth and retained hearing. MRI disclosed 5
occult tumours in four affected individuals: 2 convexity meningiomas, 2 spinal
schwannomas, and one with appearance of intraspinal glioma. Eight tumours of six
members were operated between 1969 and 1992 without tumour recurrence. The eight
operated vestibular tumours, and the intraspinal tumour (radiologically a glioma) analyzed
at autopsy, were schwannomas (I, II). Characteristic for the mild disease was the late
onset of hearing deterioration at ages 40 to 50 years with slow progression at few dB per
year. The late-onset tumorigenesis is highlighted by the absence of tumours in three
asymptomatic adult members with NF2 at age 29 to 41 years or before age 21 years. The
tumour progression was slow and only one vestibular schwannoma grew large enough to
occlude the fourth ventricle and cause hydrocephalus, and none of the affected members
have died of the disease. Furthermore, the tumours demonstrated lower proliferation
indices than a series of unrelated NF2-associated vestibular schwannomas (II). Minimal
other manifestations of NF2 were present. One member had minor posterior lens opacity
and a Lisch nodule, and had presented at age 11 with an apparent paraganglioma (glomus
tumour).
5.2. Splice site NF2 gene mutation, aberrant transcript and
aberrant merlin associated with mild phenotype (II)
The mild and uniform disease in this large pedigree was shown to be caused by a novel
mutation in the NF2 gene at intron 15 splice donor site (1737 + 3 a -› t). The mutation
was identified by the minisequencing method in all NF2 family members previously
identified with linkage analysis. The mutation resulted in splicing out of exon 15 and
production of two RNA transcripts: a novel mutant transcript with exon 16 and 17, and
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the overexpression of isoform III, normally detected at a low level. Both transcripts
encode for the C-terminus of isoform III. Immunoblotting of the patient fibroblasts and
tumour tissue demonstrated variant merlin with altered C-terminus at an intensity
comparable to the wild-type protein. Loss of heterozygosity, a common somatic event in
schwannomas, was studied in three rather quiescent tumours of this family, and all
showed loss of the wild-type NF2 allele.
5.3. Characterization of patients with multiple schwannomas
(III)
Thirteen patients with at least one spinal and an additional spinal or peripheral
schwannoma were identified from a cohort of 243 patients operated on for spinal
schwannoma. Five of the thirteen patients appeared to have classical NF2. The remaining
eight patients with multiple schwannomas, and one with no spinal but four peripheral
schwannomas, were further studied to reveal any other manifestations of NF2. In the
histological reanalysis, all tumours were schwannomas. The tumours demonstrated, more
often than sporadic control schwannomas, a lobular appearance and frequent Verocay
bodies, signs suggestive of NF2. The patients were middle-aged at first surgery (median
43.5 years) and all were sporadic cases, i.e. no positive family history of schwannomas,
NF2, NF1 or associated features. In a thorough clinical study, including MRI of the
neuraxis after a median follow-up time of 9.9 years, none had any cutaneous, ocular or
tumour manifestations suggestive of NF1 or NF2. In the follow-up, the periferal tumours
did not increase in number, and the number of spinal tumours increased only in one case
from 3 to 8 during 21 years, and no intracranial tumours developed despite advanced age
(five cases between 55 and 68 years). Two of the nine schwannomatosis patients had
died, both from unrelated causes at 50 and 65 years. No germ-line mutations could be
detected by sequencing all 17 exons of the NF2 gene from lymphoblast-derived DNA of
the seven schwannomatosis patients who were alive.
5.4. Cell biology of merlin compared with the ERM protein
ezrin (IV)
5.4.1. Subcellular distribution
Transfected merlin and endogenous ezrin in COS-1 cells, and the endogenous merlin and
ezrin in U251 glioma cells revealed a highly overlapping distribution underneath the plasma
membrane and in cell surface projections and blebs. Merlin and ezrin showed an almost
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identical staining pattern in COS-1 cells grown on fibronectin. The localization was quite
similar at intracellular structures which sometimes stained in a network-like or filamentous
pattern, and at regions near the cell membrane. In COS-1 cells grown on glass coverslips,
filopodia and the ruffling membrane which contained merlin often lacked ezrin, although in
untransfected and mock-transfected COS-1 cells these structures contained ezrin. This
suggests that transfected merlin may relocate ezrin from its normal subcellular regions under
certain growth conditions.
5.4.2. Cytoskeletal association
In transfected COS-1 cells, merlin colocalized with some of the F-actin filaments in the cell
body and with membrane-associated blebs, but most of the F-actin-containing
microfilaments showed no reactivity for merlin. Cytochalasin B treatment resulted in
disruption of the actin-containing filaments and clustering of F-actin, and major
reorganization of merlin and ezrin. In peripheral areas of the cells, especially in retraction
fibres, merlin was accumulated in clusters which always contained F-actin and in most
cases ezrin. On the other hand, many F-actin clusters, particularly in the cell body, were
devoid of merlin. Also unclustered merlin, which presumably represents a detergent-soluble
fraction, could be detected.
In transfected COS-1 cells, extracted with Triton X-100, the proportion of both proteins
in the non-extractable cytoskeleton-associated fraction varied between 20 and 25%.
Confocal microscopy of COS-1 cells, briefly treated with detergent before fixation,
revealed that merlin and ezrin were retained in the cell ghosts and their distribution was
overlapping. A faint network-like staining pattern of merlin and ezrin was more evident in
detergent-treated cells than in untreated cells, presumably due to removal of the soluble
cytoplasmic protein.
5.4.3. Association with CD44
The reported linkage between CD44 and the ERM proteins79,198 prompted us to study
whether endogenous CD44 in COS-1 cells would colocalize with merlin, and whether
merlin expression would affect CD44 distribution. In untransfected or mock-transfected
cells, CD44 was distributed diffusely on the cell surface or colocalized with ezrin in delicate
microvillar structures. In contrast, in cells transfected with merlin, CD44 and merlin were
accumulated at structures resembling thick microspikes and blebs at the dorsal membrane.
The CD44/merlin clusters were retained in cells subjected to detergent prior to fixation,
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suggesting that CD44 in these structures is associated with the cytoskeleton via merlin.
When lysates of CD44 Namalwa-transfectants were reacted with recombinant GST-merlin
immobilized on glutathione beads, a binding of CD44 was detected.
5.4.4. Morphogenic effects
Many of COS-1, 293 and CHO cell transfectants were elongated and demonstrated
merlin-positive cell membrane blebs, not seen in ß-galactosidase transfectants. CHO cells,
least variable in morphology, were most suitable for a quantitative morphogenic analysis
of the maximum diameter, surface attachment area and cell elongation after merlin or ß-
galactosidase transfection. The transfected CHO cells were much more elongated
(p<0.0001) when expressing merlin than ß-galactosidase, but the cell surface attachment
area was not affected.
6. DISCUSSION
6.1. Large pedigree with very mild and uniform NF2 (I)
The family described here presents a very mild course of NF2 with slowly growing and
late-onset vestibular schwannomas, no marked hearing deficit before 40 to 50 years of
age, and few other tumours. NF2 is arbitrarily subdivided into mild, intermediate and
severe forms, and in the mild form NF2 presents at age   > 30 years59. Compared to the
severe form, the milder disease associates with later mean age of onset of hearing loss (33
years vs. 22 years) and mean age at death (61 years vs. 42 years)141. The course of NF2
in the members of this family demonstrated remarkable clinical uniformity, which has
been noted in NF2 families54,55,142. However, reports of families with both mild and
severe phenotypes17,98,141,171, and monozygotic twins with a non-identical disease18
suggest that epigenetic, stochastic or environmental factors may modify the phenotype.
However, in this large NF2 pedigree with eleven affected and six as yet manifestation-
free individuals, it is unlikely that the mild phenotype would be due to genetic factors
other than NF2. Furthermore, there is no evidence of modifying genes or environmental
factors in NF2.
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6.2. Splice site mutation causes mild NF2 (II)
In general, NF2 provides an ideal model for the genotype-phenotype analysis of a tumour
suppressor gene. Since somatic inactivation of the NF2 gene is typically a large loss in
22q, the inherited germ-line NF2 mutation should primarily dictate the clinical outcome.
The penetrance of NF2 is virtually complete, and limited variation of the phenotype is
seen within a single family. The family in this study is one of the few large and well-
characterized NF2 pedigrees and thus especially suitable for genotype-phenotype
correlation. This mild NF2 disease was caused by a splice donor site mutation at intron 15
in the NF2 gene. In accordance, mild NF2 has been associated with exon 15 splice donor
mutations and skipping of exon 1597,162. In these families the disease course is similar,
although clinical variability frequently associates with splice site mutations99. The
mutation gave rise to the expression of two transcripts in fibroblasts, a novel mutant
transcript with exon 16 and 17, and the overexpression of isoform III. Also previously,
overexpression of isoform III has been seen to occur with intron 15 splice donor
mutations (1737 AGgt to ATgt and 1737+12 ins 220 bp), but no novel transcripts were
detected88,97. This might be due to different splicing mechanisms in the tissues analyzed
(fibroblasts vs. lymphoblasts and schwannoma), or due to different transcriptional
consequences.
The expression of the aberrant transcripts and merlin in the patient fibroblasts at levels
comparable to wild-type protein and in a schwannoma shown in this study, agrees with
the concept that certain mutations, theoretically missense or in-frame changes, may result
in protein products with partially retained tumour suppressor function69. This is
supported by the presence of truncated and full-length merlin in a subset of
schwannomas71,75,85. This highlights the importance of studying the mutational
consequences at the protein level, which may aid in the prediction of the disease course
and reveal domains important for the tumour suppressor function.
In the presented family, both transcripts from the mutant allele encode the C-terminus of
isoform III. The decreased proliferation rate of tumours in association with the C-
terminus of isoform III suggests that this isoform has partially retained the tumour
suppressor function. So far, there is no information on the function of isoform III.
Interestingly, transgenic mice expressing merlin truncated at the C-terminus demonstrated
no tumorigenesis, and also the growth suppressive functions of Drosophila merlin are
contained within the N-terminal domain65,107.
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6.3. Sporadic schwannomatosis is not classical NF2 (III)
Multiple schwannomas have been suggested to represent a third form of NF,
schwannomatosis, although some authors have considered it to be an attenuated form of
NF258,147. In agreement with previous reports on sporadic schwannomatosis58,120,
139,215
, the patients in this study had multiple schwannomas but no other manifestations
of NF2 including meningiomas and ocular abnormalities, which are found in >50% and
>90% of NF2 cases, respectively54,131,141,150. The favourable prognosis, presentation
in middle-age and no intracranial tumours has been also recognized by
others58,82,89,120,139,215. This does not distinctively rule out NF2 because, in NF2,
tumours may initially appear elsewhere than on the vestibular nerves, and in late-onset
families, members with an NF2 gene mutation without tumour manifestations are
occasionally found in their seventies55,57,162. Although the clinical aspects in this study
were not supportive of classical NF2, the schwannomas displayed histological features
associated with NF2: more lobular "grape-like" growth pattern, and more Verocay
bodies, uncommon in sporadic schwannomas186. Patients with two schwannomas (three
of the nine cases in our series) may represent chance occurrence against the annual
incidence of 0.3 - 0.4/100 000 of symptomatic spinal schwannomas177 (the incidence of
occult spinal or peripheral schwannomas is unknown). None of our patients had a
positive family history, although a subset of schwannomatosis is known to be
familial58,89,215 as also shown by Antinheimo in a population-based study in Finland.
Schwannomatosis families have been shown to associate with the NF2 gene in genetic
linkage analyses58.
Recently, the molecular analysis of tumours from schwannomatosis patients suggested
four alternative molecular backgrounds in schwannomatosis89. (1) The disorder may not
be due to the inactivation of the NF2 gene, as three tumours of one individual with a
highly aggressive disease did not display any NF2 gene abnormality, seen in > 90% of
schwannomas88. This is supported by the detection of schwannomas with no alterations
in the NF2 gene but deletions elsewere on 22q36. (2) It may be due to somatic mosaicism,
as multiple tumours at anatomically different locations displayed the same NF2 mutations,
and in one case the mutation was detected at an extremely low level in the lymphocytic
lineage89. Indeed, somatic mosaicism has been recently proposed to be a fairly common
(15% of cases) phenomenon in NF260. (3) Multiple tumours may be a noncontinuous
spread of a single tumour, when tumours with the same NF2 mutations are restricted to a
confined anatomical region. This has not been shown for schwannomas, but may explain
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multiple meningiomas in sporadic cases187,206,220. (4) Schwannomatosis may be due to
an inherited predisposition to schwannomas, because in some familial cases tumors
display different somatic mutations but LOH at always the same allele89.
No germ-line NF2 gene mutations were found in the present series, in line with other
reports of sporadic or familial schwannomatosis58,89. Thus, classical NF2 mutations are
unlikely, although the current mutation detection methods miss one-third of the
mutations142. Occasional NF2 mutations have been identified in schwannomatosis82,147,
but because some of the cases have later turned to be NF2, there is a high probability of
late-onset classical NF2 in these cases97-99. Somatic mosaicism, shown to occur
occasionally in sporadic schwannomatosis89, could not be excluded in this study because
mutation search by exon sequencing does not detect mutations at a very low level. Also,
lower mutation detection rates in mild than in severe NF2142 suggest that other mutational
mechanisms not detectable by the current methods, such as large deletions of the NF2
gene, may be involved in schwannomatosis. Altogether, sporadic schwannomatosis
seems to be distinct from the classic NF2, with a more favourable prognosis.
Based on the current knowledge and our observations, slight modifications can be
suggested to the clinical diagnostic criteria for schwannomatosis, as proposed by Jacoby
et al.89 to strengthen the discrimination to mild NF2, segmental NF2 and chance tumour
occurrence. Furthermore, evidence of any intracranial tumours, especially meningiomas at
young age, or other NF2 manifestations should raise suspicion of classic NF2.
The modified criteria of schwannomatosis:
1. three or more pathologically diagnosed schwannomas without an anatomically limited
distribution and
2. lack of radiographic evidence of vestibular schwannoma, at age >18 years, and
meningioma at age < 30 years
6.4. Merlin is a functional member of the ERM protein family
(IV)
The NF2 tumour suppressor protein, merlin, shares structural characteristics with the
ERM family of membrane-organizing proteins. Thus far, limited information has been
available on its cellular distribution and functions. This study shows that merlin has a
subcellular distribution beneath the cell membrane and at specialized cellular protrusions,
similar to that of ERM-family members6,62,140,214. The observed distribution is in
accordance with the preferential membrane-bound localization of the transfected merlin at
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the dorsal surface of COS-1 cells46 and at the ruffling edges in primary meningioma
cells66. Furthermore, our experiments demonstrated that merlin in most subcellular
regions colocalized with ezrin. The result is not surprising as ezrin, radixin and moesin
are able to dimerize with each other7,63,143. Furthermore, an interaction between merlin
and ezrin and the ability of head-to-tail dimerization in vitro and in vivo has been
demonstrated67. The apparent discrepancy in staining results with Gonzalez-Agosti et
al.66, who found a non-overlapping distribution for merlin, ezrin and moesin in a primary
meningioma cell line, probably reflects cell type or stimulation specific variation in ERM
protein distribution. We also observed a difference in the distribution in response to
different growth substrata. When COS-1 cells were grown under conditions which result
in poor development of the F-actin network, merlin appeared to redistribute ezrin from
sites where it is located in untransfected cells. This is of interest as ERM proteins
demonstrate interchangeability and functional redundancy78,194. For instance,
overexpressed radixin displaces moesin from microvilli and filopodia78. In this respect,
merlin shows functional similarity to other members of the ERM family.
The association of merlin with the cytoskeleton was indicated by its resistance to detergent
extraction and by coclustering with F-actin after cytochalasin B treatment. The partial
detergent-insolubility was alike the behavior of ezrin and in line with previous reports5,46.
The presence of merlin in the soluble and cytoskeleton-associated fraction, like other
ERM proteins, suggests that also merlin undergoes a change in conformation that could
coincide with the translocation between the soluble pool and the membrane-skeleton. The
ERM proteins are in their phosphorylated form when associated with the membrane-
skeleton and revert to the soluble pool following dephosphorylation33,122,200,204.
Intrestingly, merlin has been shown to change rapidly between phosphorylated and
unphosphorylated state in response to growth inhibition stimuli by serum starvation and
loss of cell adhesion179.The association between merlin and F-actin-containing
cytoskeleton is evident, but whether a direct interaction exists between merlin and actin
remains to be determined. The C-terminal F-actin-binding site of ERM proteins (ezrin
residues 552-585) is only partially retained in merlin, but the villin/ERM actin-binding
motif at this site is conserved201,202. Evidence against a funtional actin-binding site is
suggested when C-domain expressed as GST-fusion proteins or by in vitro
transcription/translation does not bind polymerized actin217(Turunen, unpublished).
Recently, we have detected that merlin interacts with globular β-actin and filamentous α-
actin by the N-domain residues 1-339 (Zhao, Sainio, Grönholm, Carpén, unpublished),
in line with Xu et al., who detected an actin-binding domain at residues 178-367217. It is
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tempting to propose that the homologous RKKK cluster (residues 299-328 in merlin),
critical for the actin-binding of ERM proteins, is the likely actin binding site also in
merlin124,156. Furthermore, merlin (residues 519-590 of isoform II) binds also to another
component of the cytoskeleton, βII-spectrin172.
The ERM family members bind to the cytoplasmic domain of transmembrane glycoprotein
CD4479,198, and in this study such an association was also shown for merlin.
Furthermore, we have recently verified the direct interaction between CD44 and the N-
terminal domain of merlin by the yeast two-hybrid method (Sainio, Grönholm,
unpublished). The interaction of merlin and CD44 and merlin-dependent redistribution of
CD44 suggests that merlin could regulate the adhesive functions of transmembrane
molecules by regulating their distribution. The aberrant expression of CD44 is associated
with tumour progression and metastasis158. The intracellular interactions of the
cytoplasmic domain of CD44 are known to regulate the ultrastructural localization of
CD44 on the cell surface, and to affect cell motility and cell-matrix adhesion205. Thus, the
tumour suppressor mechanism of merlin could be comparable to that of the APC protein,
which in association with the E-cadherin/catenin complex, is associated with colon
carcinogenesis19. This would provide an explanation to the impairment of cell adhesion
subsequent to antisense oligonucleotide inhibition of merlin expression or expression of
mutant merlin83,103. In an analogous model, transfection of ezrin to thymoma cells leads
to clustering of ICAM-2 and an increase in ICAM-2-dependent adhesion77. Another
mechanism may be that merlin and ERM proteins via their interaction with molecules
containing PDZ domains (Na+-H+ exchanger regulatory cofactor, hNE-RF or EBP50)
regulate the outside-in signalling events by clustering transmembrane proteins and key
components of downstream transduction pathways34,136,152.
The membrane-cytoskeleton linker mechanism of merlin is thus similar to that of ERM
proteins (Figure 3). Interestingly, NF1 tumour suppressor protein, neurofibromin, has
recently been shown to associate with epithelial cell adhesion site components, CK 14,
desmoplakin and β4-integrin in differentiating keratinocytes104. Thus, neurofibromin
may also have a role in connecting cytoskeletal components and cell adhesion molecules.
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Figure 3 .  Membrane-cytoskeleton linker model for merlin. In the cortical cytoskeleton, merlin and
ERM proteins form head-to-tail oligomers. They interact with cytoplasmic tails of transmembrane
adhesion molecules (CD44) with the N-terminal FERM domains. An F-actin binding site in FERM-
domain anchors actin microfilaments.
A major function of ERM proteins is the regulation of dynamic cell surface processes. In
present experiments, transfected merlin induced morphological changes which do not
occur with wild-type ezrin or radixin78,124. However, in non-adherent thymoma cells,
transfected wild-type ezrin induces cells to form uropod-like extensions77. Transfected
cells contained membrane blebs and their cell body was significantly elongated. Such
changes in cell length must be associated with reorganization of the cytoskeleton,
apparently regulated by merlin. The morphogenic effect of merlin is also seen in NIH-3T3
transfectants116. In further characterization of the merlin domains responsible for the
morphogenic effects, such as long cell surface projections or blebbing (Zhao, Sainio,
Carpén, unpublished), revealed striking similarities with the morphogenic effects induced
by expressed domains of ezrin124,125.
7. SUMMARY AND CONCLUSIONS
Inactivation of the neurofibromatosis 2 (NF2) tumour suppressor gene leads to the
development of multiple nervous system tumours, accompanied by loss of the NF2
protein, merlin or schwannomin. The severity of the disease varies between patients, but
the biological basis of this variation is poorly understood. We studied the genotype-
phenotype correlation in a large pedigree with an extremely mild and uniform disease, the
molecular background of schwannomatosis, and the normal function of NF2 gene protein
product, merlin.
In a large NF2 pedigree, the disease course was very mild and uniform, manifesting as
late-onset slowly growing bilateral vestibular nerve schwannomas and minimal other
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manifestations. This phenotype is caused by a novel mutation in the NF2 gene at intron
15 splice donor site (1737 + 3 a -› t). The mutation resulted in splicing out of exon 15 and
production of two transcripts encoding for the C-terminus of isoform III and expression
of variant merlin with altered C-terminus. In association with exceptionally mild NF2,
this suggests retained tumour suppressor activity for the “mutant” protein and isoform III.
The detection of expressed mutant proteins in fibroblasts may provide useful information
in the prediction of the clinical outcome of individual mutations.
Further, we studied whether germ-line NF2 gene mutations were involved in the etiology
of schwannomatosis, which manifests as multiple schwannomas but not at vestibular
nerves. In this study, nine cases of sporadic schwannomatosis presented tumours at
middle-age, lacked other clinical manifestations of NF2, and had a favourable prognosis.
There were no detectable germ-line mutations in the NF2 gene. Thus, schwannomatosis
seems to represent a separate clinical entity from NF2, although the molecular background
may associate with the NF2 gene.
To understand the tumour suppressor mechanism of the NF2 gene protein product,
merlin, we studied its normal function in comparison to ezrin, the prototype member of
the ERM family. In cultured cells, merlin was codistributed with ezrin and localized
subcellularly underneath the plasma membrane at the cortical cytoskeleton in a pattern
typical of ERM proteins. Merlin colocalized with the transmembrane adhesion molecule,
CD44, and bound to CD44 in vitro. Merlin was, by several criteria, associated with the
cytoskeleton, particularly with F-actin. The interaction was indicated by partial
colocalization, cytochalasin B-induced coclustering, and retention of merlin in the
detergent-insoluble fraction. Merlin overexpression induced morphogenic changes such
as membrane extensions and blebs, and cell elongation. Thus, merlin is not only
homologous with ERM proteins, but possesses membrane-organizing properties
characteristic of ERM-family members, and also affects cell morphology. Based on these
results, merlin appears to act as a dynamic anchor protein between the cell surface and the
cytoskeleton, and possesses functional properties of ERM family members, linkers
between plasma membrane molecules and the cytoskeleton. Therefore, merlin is a unique
type of tumour suppressor protein. Its mechanism of action may extend from being a
structural protein to the coordination of adhesion and cell signalling pathways, functions
recently demonstrated for ERM proteins.
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